The Business Research Company’s 2026 market reports combine market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights to deliver research that is more actionable and strategically valuable.
Glucagon-like Peptide 1 Market Size Review: What Shaped Past Growth And What Will Drive Future Expansion?
The glucagon-like peptide 1 market has experienced substantial growth in recent years. Projections indicate a rise from $22.06 billion in 2025 to $23.88 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by factors such as the increasing prevalence of diabetes, a global surge in obesity rates, the growing acceptance of injectable peptide therapies, the broadening of endocrinology treatment options, and the availability of branded glp-1 drugs.
The glucagon-like peptide 1 market is projected to experience substantial expansion in the coming years, with its size anticipated to reach $33.26 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.6%. This projected growth during the forecast period is attributed to several factors, including a heightened demand for weight management therapies, increasing investments in peptide drug innovation, the expansion of oral peptide delivery technologies, a growing focus on chronic disease management, and the increasing adoption of personalized medicine. Key trends expected in this period involve the rising adoption of GLP-1 therapies for obesity management, the increasing development of oral glp-1 formulations, a growing emphasis on long-acting peptide drugs, the expansion of combination therapy approaches, and enhanced patient-centric drug delivery systems.
Access Free Sample Pages From The Glucagon-like Peptide 1 Market Report 2026:
Understanding The Main Driver Of The Glucagon-like Peptide 1 Market
A growing focus on personalized medicine is projected to fuel the expansion of the glucagon-like peptide 1 (GLP-1) market in the future. This approach involves medications designed to prevent, identify, or manage illnesses by leveraging insights into an individual’s genetic makeup or protein characteristics. Personalized medicine enables the customization of GLP-1 formulations and dosage levels to suit the specific requirements and choices of each patient. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Among these newly approved personalized treatments for 2023 were also seven cancer drugs and three for various other diseases and conditions. Consequently, the heightened emphasis on personalized medicine is a key factor propelling the expansion of the glucagon-like peptide 1 (GLP-1) market.
Glucagon-like Peptide 1 Market Segment Mapping For 2026 And Beyond
The glucagon-like peptide 1 market covered in this report is segmented –
1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems
What Key Trend Is Expected To Shape The Glucagon-like Peptide 1 Market Over The Forecast Period?
Leading companies within the glucagon-like peptide 1 market are concentrating on developing technological advancements to boost therapeutic effectiveness, safety, and ease of use for patients in weight management and diabetes care. Glucagon-like peptide 1 (GLP-1) therapies are injectable, peptide-based medications that imitate the function of the endogenous hormone GLP-1 to regulate appetite, glucose metabolism, and body weight. For instance, in March 2024, Novo Nordisk A/S, a pharmaceutical company based in Denmark, introduced Wegovy, which is the first and only once-weekly GLP-1 therapy tailored for weight management. This therapy, developed through the STEP Phase 3a clinical trial program, exhibited a safe and well-tolerated profile and is designed to help individuals with obesity achieve and maintain weight loss. By offering a convenient weekly dosing regimen, Wegovy improves patient adherence and addresses the increasing demand for innovative, effective obesity treatments.
Glucagon-like Peptide 1 Market Major Players And Industry Competition Overview
Major companies operating in the glucagon-like peptide 1 market are Novo Nordisk, Eli Lilly And Company, Pfizer Inc., AstraZeneca Plc, Sanofi S.A., Boehringer Ingelheim International GmbH, Merck And Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Johnson And Johnson, Amgen Inc., GlaxoSmithKline Plc, Novartis AG, Bayer AG, AbbVie Inc., Bristol Myers Squibb Company, Biocon Limited, Hanmi Pharmaceutical Co., Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Zealand Pharma A/S, Gan And Lee Pharmaceuticals Co., Ltd.
Full Glucagon-like Peptide 1 Market Report: Market Size, Trends, Segments And Key Players:
Glucagon-like Peptide 1 Market Geographic Segmentation: Regions Covered In The Report
North America was the largest region in the glucagon-like peptide 1 market in 2025. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
